These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 17987653)

  • 21. [Duodenal levodopa infusion for advanced Parkinson's disease in Finland 2006-2010].
    Pursiainen V; Pekkonen E
    Duodecim; 2012; 128(16):1707-15. PubMed ID: 23025155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Continuous treatment with levodopa of Parkinson disease].
    Lundqvist C; Nystedt T; Reiertsen O; Grotli R; Beiske AG
    Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2638-40. PubMed ID: 16215609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications.
    Eggert K; Schrader C; Hahn M; Stamelou M; Rüssmann A; Dengler R; Oertel W; Odin P
    Clin Neuropharmacol; 2008; 31(3):151-66. PubMed ID: 18520982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
    Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
    Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A; Tolosa E
    Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intraduodenal infusion of levodopa].
    Valldeoriola F; Cámara A
    Rev Neurol; 2010 Jul; 51(1):41-8. PubMed ID: 20568067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 28. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excellent response to apomorphine in Parkinsonism with optic atrophy unresponsive to oral antiparkinsonian medication.
    Deutschländer A; Asmus F; Marelli E; Klopstock T; Gasser T; Bötzel K
    Mov Disord; 2006 Sep; 21(9):1523-5. PubMed ID: 16755578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion.
    Santos-García D; Macías M; Llaneza M; Grande M; de la Fuente-Fernández R
    Mov Disord; 2011 Feb; 26(3):558-9. PubMed ID: 20960480
    [No Abstract]   [Full Text] [Related]  

  • 31. Should levodopa be infused into the duodenum?
    Mouradian MM
    Neurology; 2005 Jan; 64(2):182-3. PubMed ID: 15668409
    [No Abstract]   [Full Text] [Related]  

  • 32. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion.
    Isacson D; Bingefors K; Kristiansen IS; Nyholm D
    Acta Neurol Scand; 2008 Dec; 118(6):379-86. PubMed ID: 18547273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients.
    Sánchez-Castañeda C; Campdelacreu J; Miró J; Juncadella M; Jaumà S; Calopa M
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):250-1. PubMed ID: 19887096
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 37. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure.
    Nyholm D; Lewander T; Johansson A; Lewitt PA; Lundqvist C; Aquilonius SM
    Clin Neuropharmacol; 2008; 31(2):63-73. PubMed ID: 18382177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease.
    Westin J; Nyholm D; Groth T; Dougherty MS; Yerramsetty PK; Palhagen SE
    Parkinsonism Relat Disord; 2006 Dec; 12(8):509-13. PubMed ID: 16731025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
    Mizuno J; Kato S; Watada M; Morita S
    Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Parkinson's disease with orphenadrine alone and in combination with L-dopa.
    Bassi S; Albizzati MG; Calloni E; Sbacchi M; Frattola L
    Br J Clin Pract; 1986 Jul; 40(7):273-5. PubMed ID: 3741741
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.